Some serious medical conditions require life-saving treatment with high doses of synthetic glucocorticoids such as dexamethasone. A substantial number of patients subjected to this treatment develops psychosis, mood disturbances, or sleep problems. A recent clinical trial demonstrated that dexamethasone therapy for young patients with acute lymphoblastic leukemia caused severe adverse psychological effects and sleep disturbances in about 30% of these patients. These side effects were ameliorated by coadministration of a low dose of the naturally occurring glucocorticoid hormone cortisol. This paradoxical finding was predicted by the idea that the synthetic glucocorticoid targets the glucocorticoid receptor, causing suppression of cortisol secretion and, thus, depletion of the brain mineralocorticoid receptor (MR) of its endogenous ligand. The refill of the unoccupied brain MR with physiological amounts of cortisol ameliorates the dexamethasoneinduced psychological side effects. In the present report, we discuss the mechanistic underpinning of the MR refill concept in glucocorticoid therapy. (Endocrinology 158: 448-454, 2017) S ynthetic glucocorticoids are commonly prescribed medications to treat inflammatory and immune diseases such as rheumatoid arthritis, Crohn's disease, and vasculitis, including temporal arteritis. These steroids are also used to prevent possible edema and inflammation during cranial surgeries, to suppress rejection of tissue transplants, and to treat leukemia. The synthetic glucocorticoids are very efficacious and are considered relatively safe when used at low doses (1, 2). However, in moderate to high doses, the steroids can cause severe side effects, including obesity, osteoporosis, hypertension, and serious behavioral, cognitive, and psychological disturbances (3). Negative effects on sleep and mood occur in $15% of the patients when the doses are high and the treatment is long-lasting, such as dexamethasone therapy for acute childhood leukemia (4). An analysis involving .350,000 patients taking synthetic glucocorticoids registered in general practices in the United Kingdom from 1990 to 2008 showed a sevenfold increase in suicide or suicide attempts, a twofold increase in depression, a fourfold increase in mania, and a fivefold increase in delirium, confusion, and disorientation (5). A recent proof of concept study demonstrated that the severe adverse effects on psychology and sleep from the synthetic glucocorticoid dexamethasone are ameliorated by coadministration of the naturally occurring glucocorticoid cortisol or hydrocortisone (4). For this purpose, cortisol was administered during a brief 5-day dexamethasone course as an add-on treatment in low doses, mimicking the replacement therapy used for adrenally deficient patients.
S
ynthetic glucocorticoids are commonly prescribed medications to treat inflammatory and immune diseases such as rheumatoid arthritis, Crohn's disease, and vasculitis, including temporal arteritis. These steroids are also used to prevent possible edema and inflammation during cranial surgeries, to suppress rejection of tissue transplants, and to treat leukemia. The synthetic glucocorticoids are very efficacious and are considered relatively safe when used at low doses (1, 2) . However, in moderate to high doses, the steroids can cause severe side effects, including obesity, osteoporosis, hypertension, and serious behavioral, cognitive, and psychological disturbances (3) . Negative effects on sleep and mood occur in $15% of the patients when the doses are high and the treatment is long-lasting, such as dexamethasone therapy for acute childhood leukemia (4) . An analysis involving .350,000 patients taking synthetic glucocorticoids registered in general practices in the United Kingdom from 1990 to 2008 showed a sevenfold increase in suicide or suicide attempts, a twofold increase in depression, a fourfold increase in mania, and a fivefold increase in delirium, confusion, and disorientation (5) . A recent proof of concept study demonstrated that the severe adverse effects on psychology and sleep from the synthetic glucocorticoid dexamethasone are ameliorated by coadministration of the naturally occurring glucocorticoid cortisol or hydrocortisone (4) . For this purpose, cortisol was administered during a brief 5-day dexamethasone course as an add-on treatment in low doses, mimicking the replacement therapy used for adrenally deficient patients.
Differential Binding of Dexamethasone and Cortisol to Brain Receptors
To understand how cortisol could alleviate some of the side effects of synthetic glucocorticoids, it is important to compare the receptor pharmacology of the endogenous and exogenous compounds (6) . The 2 endogenous glucocorticoids are cortisol and corticosterone. Rats and mice exclusively produce the hormone corticosterone; however, in humans, 95% of the circulating glucocorticoids is cortisol and 5% corticosterone (7, 8) . Their levels are regulated by the hypothalamus-pituitary-adrenal (HPA) axis to support the organisms' diurnal activity cycle and sleep pattern and adaptation to stress (9) .
Cortisol and corticosterone can, in the brain, bind to 2 types of receptors, the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR) (10, 11) . The mineralocorticoid hormone aldosterone can also bind MRs but is outcompeted by corticosterone and cortisol for binding, unless these naturally occurring glucocorticoids are enzymatically degraded by 11b-hydroxysteroid dehydrogenase type 2 (12, 13) . In the brain, most MRs are cortisol preferring, rather than, aldosterone preferring, with the exception of a few discrete neuronal populations in the nuclei tractus solitarii (NTS), the ventromedial hypothalamus, and circumventricular organs (14, 15) .
The MR and GR are members of the nuclear receptor family and act as ligand-activated transcription factors. The MR has a 10-fold greater affinity for cortisol/ corticosterone than the GR. Thus, the MR is activated by low levels of circulating cortisol/corticosterone, and the GR is activated during the circadian peak and after stress (16) . Recently, lower affinity membrane variants of the MR and GR were identified that account for the rapid effects exerted by corticosterone on excitatory transmission (17) . The combined genomic and nongenomic actions of corticosterone and cortisol mediated by the 2 types of receptors are crucial for processing of stressful information and are the key to understanding why cortisol add-on to dexamethasone therapy provides a benefit. A central issue is that the synthetic glucocorticoids that are broadly used as anti-inflammatory drugs have the GR as their therapeutic target (18) . The most potent and efficacious synthetic glucocorticoids, such as dexamethasone, have a high selectivity for the GR compared with MR binding (19) .
Negative Feedback Regulation and Emptying of Brain Receptors
A common feature of both synthetic and endogenous glucocorticoids is their potent suppression of adrenocorticotropic hormone levels. For synthetic steroids, this suppression takes primarily place at the level of the pituitary via activation of the GR (20) (21) (22) . As a consequence, activation of GRs by the synthetic steroids leads to suppression of endogenous cortisol/corticosterone secretion and to lower occupancy of MRs (Fig. 1) .
The dose of dexamethasone is very important for MR and GR occupancy in the brain. Previously, it was found that tracer doses of peripherally administered 3 H-corticosterone rather than 3 H-dexamethasone are retained by receptors in cell nuclei of the hippocampus isolated by sucrose density centrifugation (21) . We now know that dexamethasone and other synthetic glucocorticoids such as prednisolone poorly penetrate the blood-brain barrier at low doses owing to the presence of the P-glycoprotein (ATP binding casette transporter sub-family B member 1, or ABCB1) in the bloodbrain barrier (1, 2, 23, 24) . Therefore, low doses of dexamethasone suppress the HPA axis and reduce cortisol and corticosterone levels but poorly enter the brain and create a state of brain-selective adrenalectomy, in which central MRs and GRs are both underactivated (3, 25) .
Higher doses of dexamethasone will override P-glycoprotein export capacity and penetrate into the brain, occupying the central GR but not MR. At the same time, suppression of the HPA axis will be more complete, and the reduction of corticosterone and cortisol binding to the MR will become more manifest (4, 25) . This implies that dexamethasone leads to a vast skewing of brain MR/GR activation, with-in pharmacological terms-MR depletion of ligand being as great as GR overactivation. Therefore, any disadvantageous consequence of high-dose dexamethasone treatment of brain function can be the result of (1) dosedependent overactivation of GR, (2) underactivation of MR, and/or (3) an imbalance between MR and GR activation.
Brain MR and GR: Different Roles
MR expression is restricted compared with the GR, but its presence in, among others, the hippocampus, amygdala, and prefrontal cortex allows the receptors to have substantial influence over emotional and cognitive processes. MR activation promotes memory retrieval, stimulates the appraisal process, and facilitates the selection of an appropriate response to cope with stressful situations (5, (26) (27) (28) . Thus, MR activation allocates energy resources to the amygdala-based circuitry involved in processing of salient information. This also involves hippocampal-based declarative functions but, in case of an unpredictable or uncontrollable event, coping relies on a rapid MR-dependent "habitual" response mediated by the amygdala-striatal pathway (4, (29) (30) (31) . Subsequently, GR activation shifts the allocation of energy resources to the frontal cortical circuitry underlying the executive functions promoting behavioral adaptation and memory storage of the experience (6, 32, 33) . The GR is also the predominant receptor type at the negative feedback sites and the ascending brain stem serotonergic and catecholaminergic nuclei (7, 8, 34, 35) . The GR and MR sometimes cooperate and sometimes mediate opposite effects on, for example, neuronal excitability in the hippocampus, amygdala, and prefrontal cortex (9, 17, 36) . Also, neurogenesis is suppressed by overstimulation of the GR and can be rescued by MR stimulation with the potent MR agonist fludrocortisone (10, 11, 37). Thus, for the specific aspects of mental health, either over-or press.endocrine.org/journal/endounderactivation of one or both receptor types could be detrimental, which could be the case for the dexamethasone-induced depletion of the brain MR ligand. GR overactivation is often considered as a cause of psychopathology. For example, in cases of cortisol excess during Cushing disease, GR antagonism with RU486 can alleviate severe psychotic depressive symptoms (12, 13, 38) . Hypercortisolemia due to Cushing disease differs from dexamethasone treatment in that the latter leads to a greater imbalance between GR and MR activation and can, therefore, be targeted with cortisol cotreatment. At the transcriptional level, hormone-activated MR and GR can mediate the action of glucocorticoids independently, but also cooperatively (Fig. 1) . This is because the receptors have a very similar DNA binding domain and can bind as homodimers or heterodimers to glucocorticoid-responsive elements (GREs) in the rat hippocampus (14, 15, 39, 40) . In addition, both receptors can affect transcription via protein-protein interactions with other transcription factors (16, 18, 41, 42) , which are likely quite specific for each receptor type (17, 43, 44) . However, even if the MR and GR bind to the same DNA elements in the hippocampus, they might have different effects on transcription, because downstream signaling via nuclear receptor coregulators can differ for MRs and the GR (18, 45) . Moreover, transcriptional effects also depend on the ligand that binds MRs or GR (19, 46) .
The consequences of depleting the brain MR of its ligand by systemic dexamethasone treatment can, therefore, be diverse. In the hippocampus, most transcriptional effects seem to be GRE dependent (20) (21) (22) 47) ; however, all genes that depend on MR-selective GREs, MR/GR heterodimers, or MR-specific protein-protein interactions could be expected to differ in expression after the suppression of cortisol. In addition, MR-dependent nongenomic effects can disappear. Next to the loss of MR-dependent effects, it is conceivable that cortisol-induced MR/GR heterodimers are replaced by dexamethasone-induced GR homodimers, which could lead to more potent transcriptional effects. Dexamethasone might thus, via a number of mechanisms, cause increased vulnerability to stress-related psychiatric disorders, owing to severely compromised MR signaling, next to overactivation of the GR.
Effects of Cortisol Cotreatment
Emptied MRs can be refilled by supplying cortisol or corticosterone. Several experiments in humans and rodents have shown that a "refill" of MRs can reverse the effects induced by dexamethasone. Using mice, Liston et al. (48) demonstrated that brain-selective adrenalectomy as a result of low-dose dexamethasone treatment (100 mg/kg twice daily for 3 days) led to strongly reduced turnover of dendritic spines in sensorimotor cortical neurons. Refilling brain MRs via corticosterone cotreatment (5 to 10 mg/kg) prevented the reduction in spine turnover and restored memory function (21, 48, 49) .
Dexamethasone-induced depletion of cortisol binding to brain MRs was used as early as 1991 in humans in an experimental setting. To assess the mechanisms by which cortisol can affect sleep, Born et al. (50) treated volunteers with dexamethasone alone (2 mg, twice daily, expected to deplete MRs of ligand) or combined with cortisol. Dexamethasone reduced, and cortisol increased, the time in slow wave sleep (SWS). In terms of receptor contributions, this suggests that MR occupancy is necessary for optimal SWS, and nonphysiological exclusive GR activation will be detrimental. Subjects who were cotreated with cortisol and dexamethasone were not different from the control subjects, suggesting that both GR overactivation and MR underactivation can contribute to the effects observed after dexamethasone. In later studies, it was found that the potent MR agonist fludrocortisone can promote declarative memory consolidation of previously encoded information during SWS (51).
Plihal et al. (52) showed in healthy individuals that short-term exposure to dexamethasone increased arousal and had an "energizing" effect. This positive effect of dexamethasone switched to negative emotions (anger, sadness) if the treatment with the synthetic glucocorticoid was prolonged. Coadministration with cortisol counteracted this dysphoric dexamethasone effect. Cortisol enhanced a measure for "high spirits" and promoted a euphoric mood, likely via activation of MRs (52).
Cortisol Add-On Alleviates Dexamethasone-Induced Adversity in Brain
These animal and human studies form the basis for the hypothesis that depleting the MR of its ligand causes the adverse side effects seen in a clinical setting (4) . In a multicenter, double-blind, randomized controlled trial, 46 children were studied. These children received dexamethasone (oral, 2 mg/m 2 , 3 times daily for 5 days) as a part of treatment of acute lymphoblastic leukemia (ALL). The patients were also treated with cortisol or placebo in a cross-over design, using a dose regimen of 5, 3, and 2 mg/m 2 orally, which is commonly used as replacement therapy for adrenal-deficient young patients. About one-third of the patients receiving placebo treatment developed clinically important side effects concerning emotional problems on the Strengths and Difficulties Questionnaire. In these children, cortisol supplementation had a substantial ameliorating effect in the domains of emotional symptoms, conduct, and impact of stress. For some children, cortisol treatment sometimes meant the difference between "unbearable" and "bearable" (E. van den Akker, personal communication). Moreover, 20% of the children showed dexamethasone-induced clinically relevant sleep problems, which were substantially reduced by cortisol cotreatment, further adding to an increased quality of life.
A substantial interindividual variation exists in the sensitivity to the mental side effects of synthetic glucocorticoids. In the study of ALL, one-third of the children had no change in the scores for mental wellbeing. Of the 16 children with severe, clinically relevant psychosocial side effects, 7 had severe sleep problems; however, for a few children, only sleep problems were reported. These numbers seem typical for the variation in susceptibility for the mental side effects of synthetic glucocorticoids in this setting (4) . In general, uncertainty exists regarding the incidence of mental side effects (53) , in part because of the dose dependency. It is unclear to what extent vulnerability varies over time and whether it should be considered state or trait in individual patients. Regardless, for those afflicted at any point, the effects have a very serious impact.
Because one-third of the ALL patients treated with dexamethasone were free of complaints, but another onethird had severe psychosocial and sleep problems, one might wonder which patients are at risk. Warris et al. (54) excluded a slower clearance rate of dexamethasone as a cause but showed a statistically significant correlation with glucocorticoid feedback hypersensitivity in the low-dose dexamethasone suppression test. The predictive value of this correlation is, however, limited, because psychosocial and sleep problems were found in 50% and 38% of the patients, respectively. The number of patients with metabolic problems and/or high blood pressure increased substantially after dexamethasone treatment (55), but these side effects were not affected by cortisol add-on treatment.
Nevertheless, it would be relevant to measure the genetic variation in the NR3C1 and NR3C2 genes that encode MRs and GR and the co-chaperone FKBP5. Carriers of the ER22/23EK NR3C1 variant are protected against the detrimental effects of glucocorticoids, and Bcl1 polymorphism is associated with increased sensitivity (56) . The FKBP5 polymorphism predicts glucocorticoid sensitivity and can alter, in interaction with life stressors, the risk for mood and anxiety disorders (57) . Genetic variation or epigenetic changes in MR could very well play a role, because a gain-of-function haplotype of press.endocrine.org/journal/endothe NR3C2 gene has been shown to modulate stress reactivity and protect against psychopathology (58) (59) (60) . Genetic vulnerability to the detrimental effects of GR over-and MR underactivation are modulated by lifetime exposure to stressors. Early life stress has consistently been shown to change adult stress responses (61, 62) . Moreover, a history of chronic stress is known to result in an entirely different genomic organization that is reflected in altered network and behavioral responses (32, 63) . These become apparent on an acute challenge with glucocorticoids (64, 65) . Thus, interactions between genetic vulnerability and the lifetime stressor exposure that is apparent in many realms of psychopathology (66) could also account for the risk of developing psychopathological symptoms during dexamethasone therapy.
Conclusion
The efficacy of cortisol in the reduction of dexamethasoneinduced mental side effects bears promise for the large group of patients who are at risk, given the wide range of diseases that require treatment with potent synthetic glucocorticoids. It will be of interest to see the study by Warris et al. (4) replicated and extended over a longer period. With respect to the different patient populations, it remains to be established to what extent cortisol supplementation will be of benefit to patients treated with prednisolone rather than dexamethasone. Another important issue is the age of the patient groups. Also, although no peripheral effects of cortisol add-on were noted, the refill of cortisol preferring MR in heart, vessels, and fat may have consequences as well. One remaining question is whether cortisol is the best method to refill the brain MRs. One very appealing aspect is that cortisol is an endogenous compound, in contrast to the MR-preferring fludrocortisone, which might also be of benefit (67) . Corticosterone could be an interesting alternative, because it is also endogenous in humans (7, 8) and has better penetration into the rodent, rhesus monkey, and human brain (68) (69) (70) , with the additional possible advantage that it might result in fewer metabolic side effects (71, 72) .
Another issue is being able to predict who is at risk of dexamethasone adversity by considering the genotype and life history. Solving this question will not only allow targeted treatment with cortisol add-on but will also provide more general insight into how glucocorticoids affect mental wellbeing.
